Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$132.26 USD
-4.27 (-3.13%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $132.81 +0.55 (0.42%) 7:02 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Brokerage Reports
Ascendis Pharma A/S [ASND]
Reports for Purchase
Showing records 1 - 20 ( 303 total )
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Q4/FY23: YORVIPATH Launches in Germany Austria, Survey Supports Robust Uptake
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Vision 3x3 On-Track Now Onto Vision 2030; Pipeline Poised to Drive Value in ''24
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Topline Ph3 foresiGHt Results for TC-hGH/adult GHD; Focus Remains on YORVIPATH
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
EMA Review Provides Look into YORVIPATH Manufacturing, Underscores Unmet Need
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Could 2024 Finally Be Biotech''s Breakthrough Year?
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
TC-PTH NDA Resubmission Accepted; PDUFA Set for May 14, 2024
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A